Medically reviewed by Dr. Guillermo Quezada, MD – May 2026 | Regenerative Medicine specialist | Content reviewed as of March 2026
Clinical guidance: This adjunctive approach supports but does not replace conventional medical management. Patients should continue prescribed treatments under their physician’s direction.

NAD+ Working Dynamics: A Coenzyme-Centered Overview

NAD+ operates through four principal mechanisms: electron transfer for energy, PARP activation for DNA repair, sirtuin-mediated signaling, and redox balancing.

Fundamental Coenzyme Actions

Nicotinamide adenine dinucleotide (NAD+) serves as a cornerstone of cellular biochemistry. It carries electrons in redox reactions (shuttling between NAD⁺ and NADH) to generate ATP during glycolysis, the Krebs cycle, and oxidative phosphorylation. Beyond energy, NAD+ activates PARP enzymes that detect and fix DNA damage, and acts as a substrate for sirtuins—proteins that regulate stress resistance and metabolism—while also helping protect cells from oxidative stress.

Supportive reference: NAD+ metabolism and cellular roles (NIH/PMC)

Energy Metabolism (Electron Transfer)

NAD+ accepts electrons during metabolic reactions, converting to NADH. NADH then donates electrons to the electron transport chain, driving ATP synthesis. This mechanism directly fuels cellular processes.

DNA Repair (PARP Activation)

NAD+ is consumed by poly(ADP-ribose) polymerases (PARPs) to add ADP-ribose units onto target proteins, recruiting repair complexes to sites of DNA damage. This supports genomic stability.

Sirtuin-Mediated Signaling

Sirtuins (SIRT1-7) use NAD+ to remove acetyl groups from histones and other proteins, influencing gene expression, mitochondrial biogenesis, and stress resistance pathways.

Redox Balance & Oxidative Defense

The NAD+/NADH ratio reflects cellular redox state. Maintaining this balance supports antioxidant systems that neutralize reactive oxygen species.

NAD+ molecular structure & electron transfer illustration

Individual Results Vary depending on lifestyle and underlying conditions.

Adjunctive Role Relative to Stem Cell IV Therapy

Applied Regenerative Medicine Framework — Stem Cell IV Therapy serves as the core regenerative intervention. NAD+ IV Therapy is strategically integrated as an adjunctive supportive element to optimize cellular energetics, enhance metabolic conditions, and support DNA repair mechanisms.

Specifically, NAD+ works by:

  • Providing electron transfer support for mitochondrial ATP production
  • Activating PARP-mediated DNA repair pathways during regenerative processes
  • Sustaining sirtuin activity for cellular stress resilience
  • Maintaining redox balance to reduce oxidative burden
Adjunctive NAD+ IV supports cellular energy and repair dynamics

Educational Resource: NAD+ Mechanisms & Adjunctive Support

Access our detailed reference document that explains how NAD+ operates as a coenzyme in energy metabolism, DNA repair (PARP activation), sirtuin signaling, and redox balance. The guide includes citations from peer-reviewed literature and a plain‑language overview of the experimental adjunctive IV procedure.

This resource is provided for educational purposes and does not constitute medical advice. It is designed for patients and professionals seeking mechanistic understanding.

Request the Mechanisms Guide (PDF)

We respect your privacy. Your information is not shared.

Verifiable Official Sources & Citations

The following links lead to peer-reviewed literature, regulatory body information, and independent guidance. These sources provide foundational knowledge on NAD+ biochemistry and the regulatory status of experimental adjunctive therapies.

These resources are provided for informational purposes. They do not constitute an endorsement of any specific commercial therapy.

Therapeutic Position

Stem Cell IV Therapy is the core regenerative treatment. NAD+ IV Therapy is an adjunctive supportive element that works by enhancing cellular energy, DNA repair, and redox balance. All interventions are personalized to support biological mechanisms.

NAD+ IV exemplifies this adjunctive role: administered via minimally invasive techniques to optimize mitochondrial electron transfer and sirtuin pathways, creating a favorable cellular environment.

Clinical Evidence: Prospective Randomized Trial of IV NAD+

A single‑center, prospective, randomized, placebo‑controlled trial (ChiCTR2200059169) evaluated intravenous NAD+ (10 mg/day for 7 days) in 180 patients with heart failure due to ischemic cardiomyopathy. The NAD+ group showed significantly greater improvement in left ventricular ejection fraction at 1 month (45.44 ± 8.55% vs. 42.44 ± 9.09%, p = 0.024) and favorable trends in NT‑proBNP reduction and functional class. No serious infusion‑related adverse events were reported.⁠[reference:0]

View full study (Springer, 2026) | ClinicalTrials.gov identifier: ChiCTR2200059169

Potential Adverse Events & Contraindications

Common (>1% incidence) – usually mild & transient during infusion
  • Flushing (warmth sensation in chest, abdomen, or face)
  • Mild nausea or stomach discomfort
  • Transient headache or dizziness
  • Feeling of pressure in the head or stomach
  • Infusion site irritation / superficial phlebitis
Moderate to rare serious events
  • Rapid heartbeat (tachycardia) or anxiety during infusion
  • Hypotension (low blood pressure) – clinically significant in predisposed individuals
  • Significant nausea or vomiting (may require slowing or stopping infusion)
  • Chest tightness or dyspnea (rare, requires immediate evaluation)
  • Allergic reactions (including urticaria, itching, angioedema)
  • Inflammatory response (laboratory: increased WBC/neutrophils observed in some trials)⁠[reference:1]
  • Fluid and electrolyte imbalances (especially with repeated or high‑volume infusions)
Absolute & relative contraindications – NAD+ IV should NOT be given without thorough medical evaluation
  • Pregnancy or breastfeeding – safety unknown; NAD+ crosses placenta and is present in breast milk⁠[reference:2]
  • Severe chronic kidney disease (eGFR <30 mL/min) – impaired clearance⁠[reference:3]
  • Severe liver impairment (cirrhosis, acute hepatitis)
  • Active malignancy / concurrent chemotherapy – potential interactions
  • Uncontrolled hypertension or unstable cardiovascular disease
  • History of severe allergic reaction to IV medications or NAD+ components
  • Mast cell disorders – risk of severe reaction without warning⁠[reference:4]
  • Patients taking liver‑metabolized drugs (e.g., certain antidiabetics, anticoagulants, psychiatric medications) – interaction profile not fully studied

This list is not exhaustive. All potential candidates must undergo a comprehensive medical evaluation, including history, physical exam, vital signs, and relevant laboratory tests, before any NAD+ IV administration.

Important clinical notice: This adjunctive approach is not a replacement for conventional medical therapies. Patients must continue those treatments under the direction of their prescribing physician.

Regulatory status: NAD+ IV therapy for adjunctive cellular support is not approved by the U.S. FDA, Mexican COFEPRIS (for this indication), or any other regulatory agency. It is considered an adjunctive, experimental procedure. Costs are discussed only after a consultation.

Clinical Perspective

As physicians specializing in regenerative medicine, we present NAD+ mechanisms within an evidence-informed framework. This adjunctive approach supports cellular energetics and repair pathways, but does not claim to treat or cure specific diseases.

Transparent communication regarding the adjunctive nature, personalized plans, and realistic expectations remains central. Each NAD+ IV administration follows a thorough evaluation.

— Nexus Regenerative Medicine Clinical Team

Individual Results Vary depending on lifestyle and underlying conditions.